Spending by drug makers on network TV advertising dropped 10 percent in the first quarter from the year before, the sharpest quarterly fall-off in two years, according to a report in USA Today. The industry spent $388 million on network TV consumer drug ads in the first quarter, down about $44 million from last year, according to numbers from Nielsen Monitor-Plus. The 10 percent drop in network drug ad spending contrasts with a 4.2 percent first-quarter rise for network TV sales overall, Nielsen said. Much of the spending decline came from several big DTC campaigns including: *Viagra. Pfizer pulled TV ads in November after the FDA warned the ads were misleading. *Prevacid. TAP spent nothing on TV ads for the heartburn medication in the first quarter, vs. $18 million last year. *Celebrex. Ads for the drug were pulled in December following a study showing increased cardiovascular risks. *Crestor. AstraZeneca spent $1.1 million on TV ads for the anti-cholesterol drug in the first quarter, down from $9.4 million last year.